Published in Schizophr Res on May 05, 2008
Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull (2011) 1.78
Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res (2012) 1.23
Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry (2013) 1.17
Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry (2010) 1.10
Magnetic resonance imaging predictors of treatment response in first-episode schizophrenia. Schizophr Bull (2010) 1.02
The neurobiology and treatment of first-episode schizophrenia. Mol Psychiatry (2014) 0.93
Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value? Neurosci Biobehav Rev (2012) 0.81
T2 relaxation effects on apparent N-acetylaspartate concentration in proton magnetic resonance studies of schizophrenia. Psychiatry Res (2013) 0.78
Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A (1)H-MRS and pCASL study. Neuropsychopharmacology (2016) 0.77
Elevated Myo-Inositol, Choline, and Glutamate Levels in the Associative Striatum of Antipsychotic-Naive Patients With First-Episode Psychosis: A Proton Magnetic Resonance Spectroscopy Study With Implications for Glial Dysfunction. Schizophr Bull (2015) 0.77
NPAS3 variants in schizophrenia: a neuroimaging study. BMC Med Genet (2014) 0.75
Adding Sarcosine to Antipsychotic Treatment in Patients with Stable Schizophrenia Changes the Concentrations of Neuronal and Glial Metabolites in the Left Dorsolateral Prefrontal Cortex. Int J Mol Sci (2015) 0.75
Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust N Z J Psychiatry (2005) 5.17
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet (2003) 4.91
Whole-brain anatomical networks: does the choice of nodes matter? Neuroimage (2009) 4.43
Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res (2003) 3.86
Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry (2010) 3.82
Hippocampal and amygdala volumes according to psychosis stage and diagnosis: a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch Gen Psychiatry (2006) 3.62
Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr Res (2004) 3.55
Addiction, a condition of compulsive behaviour? Neuroimaging and neuropsychological evidence of inhibitory dysregulation. Addiction (2004) 3.34
Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord (2008) 2.95
Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomised controlled trials. Br J Psychiatry (2008) 2.89
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry (2005) 2.62
Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry (2006) 2.60
Schizophrenia, neuroimaging and connectomics. Neuroimage (2012) 2.49
Validation of "prodromal" criteria to detect individuals at ultra high risk of psychosis: 2 year follow-up. Schizophr Res (2008) 2.45
Hashimoto's encephalopathy : epidemiology, pathogenesis and management. CNS Drugs (2007) 2.39
Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry (2012) 2.31
Effect of long-term cannabis use on axonal fibre connectivity. Brain (2012) 2.27
Clinical staging: a heuristic model for psychiatry and youth mental health. Med J Aust (2007) 2.25
Medical comorbidity in schizophrenia. Med J Aust (2003) 2.20
Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry (2006) 2.17
Modulation of brain resting-state networks by sad mood induction. PLoS One (2008) 2.15
Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch Gen Psychiatry (2009) 2.13
Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull (2005) 2.13
Central nervous system function in youth with type 1 diabetes 12 years after disease onset. Diabetes Care (2009) 2.13
Normative data from the CANTAB. I: development of executive function over the lifespan. J Clin Exp Neuropsychol (2003) 2.12
Disrupted axonal fiber connectivity in schizophrenia. Biol Psychiatry (2010) 2.12
Consistency and functional specialization in the default mode brain network. Proc Natl Acad Sci U S A (2008) 2.12
Theory of mind impairment in schizophrenia: meta-analysis. Schizophr Res (2009) 2.05
Long-term follow-up of a group at ultra high risk ("prodromal") for psychosis: the PACE 400 study. JAMA Psychiatry (2013) 2.02
Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale. Aust N Z J Psychiatry (2012) 2.02
Gray matter abnormalities in Major Depressive Disorder: a meta-analysis of voxel based morphometry studies. J Affect Disord (2011) 2.01
Substitution Monotherapy With Levetiracetam vs Older Antiepileptic Drugs: A Randomized Comparative Trial. Arch Neurol (2012) 1.99
Progressive brain structural changes mapped as psychosis develops in 'at risk' individuals. Schizophr Res (2009) 1.98
Regional brain abnormalities associated with long-term heavy cannabis use. Arch Gen Psychiatry (2008) 1.95
Genetic influences on cost-efficient organization of human cortical functional networks. J Neurosci (2011) 1.90
Preventing the second episode: a systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. Schizophr Bull (2009) 1.85
Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis. Am J Psychiatry (2005) 1.84
Australian mental health reform: time for real outcomes. Med J Aust (2005) 1.81
Neuroanatomical abnormalities in schizophrenia: a multimodal voxelwise meta-analysis and meta-regression analysis. Schizophr Res (2011) 1.81
Cognitive impairment in affective psychoses: a meta-analysis. Schizophr Bull (2009) 1.78
Increased pituitary volume in antipsychotic-free and antipsychotic-treated patients of the AEsop first-onset psychosis study. Neuropsychopharmacology (2005) 1.76
Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. Br J Psychiatry (2008) 1.74
PACE: a specialised service for young people at risk of psychotic disorders. Med J Aust (2007) 1.72
Temporal lobe epilepsy and GEFS+ phenotypes associated with SCN1B mutations. Brain (2006) 1.72
Pituitary volume in psychosis. Br J Psychiatry (2004) 1.70
Progressive gray matter reduction of the superior temporal gyrus during transition to psychosis. Arch Gen Psychiatry (2009) 1.70
Structural brain development and depression onset during adolescence: a prospective longitudinal study. Am J Psychiatry (2014) 1.67
Impairment of olfactory identification ability in individuals at ultra-high risk for psychosis who later develop schizophrenia. Am J Psychiatry (2003) 1.67
Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial. J Clin Psychiatry (2004) 1.66
Stress, the hippocampus and the hypothalamic-pituitary-adrenal axis: implications for the development of psychotic disorders. Aust N Z J Psychiatry (2006) 1.62
Clinical characteristics and outcome in patients with psychogenic nonepileptic seizures. Psychosom Med (2010) 1.61
Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr Bull (2006) 1.54
Voxelwise meta-analysis of gray matter abnormalities in bipolar disorder. Biol Psychiatry (2010) 1.53
Frontotemporal dementia as a frontostriatal disorder: neostriatal morphology as a biomarker and structural basis for an endophenotype. Aust N Z J Psychiatry (2012) 1.53
Task-induced deactivation of midline cortical regions in schizophrenia assessed with fMRI. Schizophr Res (2007) 1.52
Pilot study evaluating the effect of massage therapy on stress, anxiety and aggression in a young adult psychiatric inpatient unit. Aust N Z J Psychiatry (2008) 1.46
Psychological needs of adolescents in the early phase of bipolar disorder: implications for early intervention. Early Interv Psychiatry (2011) 1.46
Childhood trauma and psychotic disorders: a systematic, critical review of the evidence. Schizophr Bull (2007) 1.45
Subthreshold attention-deficit/hyperactivity disorder is associated with functional impairments across domains: a comprehensive analysis in a large-scale community study. Eur Child Adolesc Psychiatry (2013) 1.42
Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion. Intensive Care Med (2012) 1.41
A tale of two cities: a neuroimaging investigation of Melbourne-Sydney rivalry comparing cortical thickness in healthy adults. Australas Psychiatry (2007) 1.40
Chronic mental illness and community treatment resistance. Australas Psychiatry (2006) 1.40
Guidelines for youth depression: time to incorporate new perspectives. Med J Aust (2010) 1.39
Testing the Ultra High Risk (prodromal) criteria for the prediction of psychosis in a clinical sample of young people. Schizophr Res (2006) 1.38
Funding for mental health research: the gap remains. Med J Aust (2011) 1.38
Psychotic-like experiences in nonpsychotic help-seekers: associations with distress, depression, and disability. Schizophr Bull (2005) 1.38
Anatomical abnormalities of the anterior cingulate cortex in schizophrenia: bridging the gap between neuroimaging and neuropathology. Schizophr Bull (2008) 1.37
Increased access to evidence-based primary mental health care: will the implementation match the rhetoric? Med J Aust (2007) 1.36
A review and new report of medial temporal lobe dysfunction as a vulnerability indicator for schizophrenia: a magnetic resonance imaging morphometric family study of the parahippocampal gyrus. Schizophr Bull (2003) 1.34
Cognitive functioning in schizophrenia, schizoaffective disorder and affective psychoses: meta-analytic study. Br J Psychiatry (2009) 1.32
Progressive changes in the development toward schizophrenia: studies in subjects at increased symptomatic risk. Schizophr Bull (2008) 1.32
The impact of cannabis use on cognitive functioning in patients with schizophrenia: a meta-analysis of existing findings and new data in a first-episode sample. Schizophr Bull (2010) 1.32
Proton magnetic resonance spectroscopy in first episode psychosis and ultra high-risk individuals. Schizophr Bull (2003) 1.30
Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull (2011) 1.30
Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch Gen Psychiatry (2011) 1.30